Pfizer Inc and Ionis Pharmaceuticals Inc have discontinued development of vupanorsen, an antisense oligonucleotide intended for cardiovascular risk reduction and the treatment of severe hypertriglyceridaemia, a condition characterised by high amounts of triglycerides in the blood. Announced on 31 January, the decision was taken despite favourable results from a recent Phase 2b study.
